Plasma-only circulating tumor DNA analysis detects minimal residual disease and predicts early relapse in hepatocellular carcinoma patients undergoing curative resection

被引:1
|
作者
Xu, Yuyan [1 ]
Cai, Jianpeng [2 ]
Zhong, Kaihang [1 ]
Wen, Yaohong [1 ]
Cai, Lei [1 ]
He, Guolin [1 ]
Liao, Hangyu [1 ]
Zhang, Cheng [1 ]
Fu, Shunjun [1 ]
Chen, Tingting [3 ]
Cai, Jinping [3 ]
Zhong, Xuefeng [3 ]
Chen, Chunzhu [3 ]
Huang, Mengli [3 ]
Cheng, Yuan [1 ]
Pan, Mingxin [1 ]
机构
[1] Southern Med Univ, Zhujiang Hosp, Gen Surg Ctr, Dept Hepatobiliary Surg 2, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Pancreatobiliary Surg, Guangzhou, Peoples R China
[3] 3D Med Inc, Med Affairs, Shanghai, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2023年 / 13卷
基金
中国国家自然科学基金;
关键词
hepatocellular carcinoma; circulating tumor DNA; minimal residual disease; plasma-only; early relapse; NOTCH SIGNALING PATHWAY; COMPREHENSIVE CHARACTERIZATION; INTRAHEPATIC RECURRENCE; CANCER-PATIENTS; RISK-FACTORS; LUNG-CANCER; EXPRESSION; GENES; PROLIFERATION; MUTATIONS;
D O I
10.3389/fonc.2023.1119744
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundMinimal residual disease (MRD) is considered an essential factor leading to relapse within 2 years (early relapse) after radical surgery, which is challenging to be detected by conventional imaging. Circulating tumor DNA (ctDNA) provides a novel approach for detecting MRD and predicting clinical outcomes. Here, we tried to construct a fixed panel for plasma-only ctDNA NGS to enable tumor-uninformed MRD detection in hepatocellular carcinoma (HCC). MethodsHere, we performed the followings: (i) profiling genomic alteration spectrum of ctDNA from the Chinese HCC cohort consisting of 493 individuals by NGS; (ii) screening of MRD monitoring genes; and (iii) performance evaluation of MRD monitoring genes in predicting early relapse in the ZJZS2020 cohort comprising 20 HCC patients who underwent curative resection. ResultsA total of 493 plasma samples from the Chinese HCC cohort were detected using a 381/733-gene NGS panel to characterize the mutational spectrum of ctDNA. Most patients (94.1%, 464/493) had at least one mutation in ctDNA. The variants fell most frequently in TP53 (45.1%), LRP1B (20.2%), TERT (20.2%), FAT1 (16.2%), and CTNNB1 (13.4%). By customized filtering strategy, 13 MRD monitoring genes were identified, and any plasma sample with one or more MRD monitoring gene mutations was considered MRD-positive. In the ZJZS2020 cohort, MRD positivity presented a sensitivity of 75% (6/8) and a specificity of 100% (6/6) in identifying early postoperative relapse. The Kaplan-Meier analysis revealed a significantly short relapse-free survival (RFS; median RFS, 4.2 months vs. NR, P=0.002) in the MRD-positive patients versus those with MRD negativity. Cox regression analyses revealed MRD positivity as an independent predictor of poor RFS (HR 13.00, 95% CI 2.60-69.00, P=0.002). ConclusionsWe successfully developed a 13-gene panel for plasma-only MRD detection, which was effective and convenient for predicting the risk of early postoperative relapse in HCC.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Postoperative minimal residual disease to predict the risk of hepatocellular carcinoma (HCC) recurrence using plasma-only circulating tumor DNA assay
    Pan, Mingxin
    Cai, Jianpeng
    Xu, Yuyan
    Zhong, Kaihang
    Chen, Tingting
    CANCER RESEARCH, 2022, 82 (12)
  • [2] Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer
    Parikh, Aparna R.
    Van Seventer, Emily E.
    Siravegna, Giulia
    Hartwig, Anna, V
    Jaimovich, Ariel
    He, Yupeng
    Kanter, Katie
    Fish, Madeleine G.
    Fosbenner, Kathryn D.
    Miao, Benchun
    Phillips, Susannah
    Carmichael, John H.
    Sharma, Nihaarika
    Jarnagin, Joy
    Baiev, Islam
    Shah, Yojan S.
    Fetter, Isobel J.
    Shahzade, Heather A.
    Allen, Jill N.
    Blaszkowsky, Lawrence S.
    Clark, Jeffrey W.
    Dubois, Jon S.
    Franses, Joseph W.
    Giantonio, Bruce J.
    Goyal, Lipika
    Klempner, Samuel J.
    Nipp, Ryan D.
    Roeland, Eric J.
    Ryan, David P.
    Weekes, Colin D.
    Wo, Jennifer Y.
    Hong, Theodore S.
    Bordeianou, Liliana
    Ferrone, Cristina R.
    Qadan, Motaz
    Kunitake, Hiroko
    Berger, David
    Ricciardi, Rocco
    Cusack, James C.
    Raymond, Victoria M.
    Talasaz, AmirAli
    Boland, Genevieve M.
    Corcoran, Ryan B.
    CLINICAL CANCER RESEARCH, 2021, 27 (20) : 5586 - 5594
  • [3] Utilization of personalized tumor-specific methylation haplotypes of circulating DNA to monitor minimal residual disease in patients with hepatocellular carcinoma undergoing curative resection
    Yang, Xin-Rong
    Guo, De-Zhen
    Zhang, Shi-Yu
    Xu, Min-Jie
    Chen, Hua
    Ma, Cheng-Cheng
    Fu, Rui-Qing
    Su, Ming-Yang
    He, Qi-Ye
    Zhang, Yun-Zhi
    Su, Zhi-Xi
    Liu, Rui
    Fan, Jia
    Zhou, Jian
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Multiomic, plasma-only circulating tumor DNA (ctDNA) assay identifies breast cancer patients with minimal residual disease (MRD) and predicts distant recurrence
    Janni, Wolfgang
    Huober, Jens
    Braun, Tatjana
    Mueller, Volkmar
    Fink, Angelina
    de Gregorio, Amelie
    Rack, Brigitte
    Friedl, Thomas W.
    Wiesmueller, Lisa
    Pantel, Klaus
    Rich, Thereasa
    Parsana, Princy
    Zotenko, Elena
    Zhang, Shile
    Huesmann, Sophia
    CANCER RESEARCH, 2022, 82 (12)
  • [5] Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment
    Parikh, Aparna R.
    Chee, Bryant H.
    Tsai, Jill
    Rich, Thereasa A.
    Price, Kristin S.
    Patel, Sonia A.
    Zhang, Li
    Ibrahim, Faaiz
    Esquivel, Mikaela
    Van Seventer, Emily E.
    Jarnagin, Joy X.
    Raymond, Victoria M.
    Corvera, Carlos U.
    Hirose, Kenzo
    Nakakura, Eric K.
    Corcoran, Ryan B.
    Van Loon, Katherine
    Atreya, Chloe E.
    CLINICAL CANCER RESEARCH, 2024, 30 (14) : 2964 - 2973
  • [6] Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer
    Tie, Jeanne
    Wang, Yuxuan
    Tomasetti, Cristian
    Li, Lu
    Springer, Simeon
    Kinde, Isaac
    Silliman, Natalie
    Tacey, Mark
    Wong, Hui-Li
    Christie, Michael
    Kosmider, Suzanne
    Skinner, Iain
    Wong, Rachel
    Steel, Malcolm
    Tran, Ben
    Desai, Jayesh
    Jones, Ian
    Haydon, Andrew
    Hayes, Theresa
    Price, Tim J.
    Strausberg, Robert L.
    Diaz, Luis A., Jr.
    Papadopoulos, Nickolas
    Kinzler, Kenneth W.
    Vogelstein, Bert
    Gibbs, Peter
    SCIENCE TRANSLATIONAL MEDICINE, 2016, 8 (346)
  • [7] Circulating Tumor DNA Detects Minimal Residual Disease and Predicts Outcome in Localized Lung Cancer
    Chaudhuri, Aadel
    Lovejoy, Alexander
    Chabon, Jacob
    Newman, Aaron
    Stehr, Henning
    Say, Carmen
    Carter, Justin
    Zhou, Li
    West, Robert
    Shrager, Joseph
    Neal, Joel
    Wakelee, Heather
    Loo, Billy
    Alizadeh, Ash
    Diehn, Maximilian
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S445 - S445
  • [8] Molecular residual disease detection with circulating tumor DNA analysis predicts relapse in patients with early stage breast cancer
    Turner, N.
    Garcia-Murillas, I.
    Chopra, N.
    Comino-Mendez, I.
    Beaney, M.
    Tovey, H.
    Cutts, R.
    Swift, C.
    Kriplani, D.
    Afentakis, M.
    Hrebien, S.
    Walsh, G.
    Johnston, S.
    Ring, A.
    Russell, S.
    Evans, A.
    Skene, A.
    Wheatley, D.
    Dowsett, M.
    Smith, I.
    CANCER RESEARCH, 2019, 79 (04)
  • [9] Postoperative circulating tumor cells: An early predictor of extrahepatic metastases in patients with hepatocellular carcinoma undergoing curative surgical resection
    Sun, Yun-Fan
    Wang, Peng-Xiang
    Cheng, Jian-Wen
    Gong, Zi-Jun
    Huang, Ao
    Zhou, Kai-Qian
    Hu, Bo
    Gao, Ping-Ting
    Cao, Ya
    Qiu, Shuang-Jian
    Zhou, Jian
    Fan, Jia
    Guo, Wei
    Yang, Xin-Rong
    CANCER CYTOPATHOLOGY, 2020, 128 (10) : 733 - 745
  • [10] Plasma Circulating Tumor DNA Sequencing Predicts Minimal Residual Disease in Resectable Esophageal Squamous Cell Carcinoma
    Liu, Tao
    Yao, Qianqian
    Jin, Hai
    FRONTIERS IN ONCOLOGY, 2021, 11